Biologics CDMO Market to grow by USD 13.26 billion from 2022 to 2027 | Research and development pipeline of biologics therapeutics to boost the market - Technavio

NEW YORK, July 6, 2023 /PRNewswire/ -- The biologics CDMO market size is estimated to grow by USD 13.26 billion from 2022 to 2027, at a CAGR of  13.97%, according to a recent market study by Technavio. North America is estimated to account for 46% of the market growth. Factors such as the US government offering reimbursements for some of the biologics, growing patient awareness about the benefits of the use of biologics, vendor collaborations, and the rising prevalence of chronic diseases in the US are significantly contributing to the biologics CDMO market growth in North America. One of the major regions in North America which is contributing to the market growth is the US, with several prominent players developing biologic therapeutics, such as  AbbVie, Elli Lilly, Merck, Pfizer, and Amgen. Hence, such factors are expected to drive the market growth in the region during the forecast period. For more insights on the historic period (2017 to 2021) and forecast market size (2023 to 2027) - Request a sample report

What's New?

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions 
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial  - buy the report!

Biologics CDMO Market - Segmentation Assessment
Segment Overview
The market is segmented by type (mammalian and microbial), product type (biologics and biosimilars), and geography (North America, Europe, Asia, and the Rest Of the World (ROW)). 

• The mammalian segment will account for a significant share of market growth during the forecast period. The process of growing animal cells in vitro in a flask or dish is known as mammalian cell culture. Some of the key types of mammalian cells are fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are mainly present within the blood, and the fibroblasts, epithelial cells, and macrophages are found in tissue. These cell cultures are widely used for the synthesis of vaccines in bulk. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Insights on the market contribution of various segments, including country and region wise historic data (2017 to 2021), and forecast market size (2023 to 2027) - Download a Sample Report

Biologics CDMO Market – Market Dynamics
Key factor driving market growth
The high research and development pipeline of biologics therapeutics drives the biologics contract development and manufacturing organization (CDMO) market growth. There is a significant investment in research and development by manufacturers to develop biologics, as it has shown great efficacy in curing severe infections, malignancies, and immunological and hormonal disorders. Monoclonal antibodies are one of the fastest-growing segments in biological therapies. Some of the key variations of monoclonal antibodies are ICT-107 for glioblastoma, VGX-3100 for cervical cancer, and NeuVax for breast cancer. Hence, such investments in R&D to treat various diseases are driving market growth during the forecast period.

Leading trends influencing the market 

Strategic alliances and partnerships with pharma companies are primary trends shaping the biologics contract development and manufacturing organization (CDMO) market. Due to the rising demand for CDMO, vendors are opting for partnerships and strategic alliances to enhance their market reach and customer base. Furthermore, vendors are highly investing in joint ventures and acquisitions to dominate the global biologics CDMO market and expand their market to new geographical areas. Hence, the increasing partnerships help to improve their technological know-how, innovate new products, and expand their presence. Hence, such factors will drive the market growth during the forecast period.

Major challenges hindering the market growth

The major challenge impeding biologics contract development and manufacturing organization (CDMO) market growth is capacity utilization and constraints. The measure of actual production compared with the potential production of the company when the capacity is completely utilized is known as capacity utilization. It plays a significant role in the manufacturing of different therapeutics, especially biological drugs, due to the complex production process. For instance, it is estimated that almost 35% of the CDMOs face minor constraints at least at one stage of the production process. Hence, such constraints are expected to hinder the market growth during the forecast period.

Insights on Market Drivers, trends, & Challenges, historic period(2017 to 2021) and forecast period(2023 to 2027)- Request a sample report!

What are the key data covered in this Biologics CDMO Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Biologics CDMO Market between 2023 and 2027
• Precise estimation of the size of the Biologics CDMO Market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Biologics CDMO Market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Biologics CDMO Market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The cancer biologics market size is expected to increase by USD 34.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.91%. Furthermore, this report extensively covers cancer biologics market segmentation by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). One of the key factors driving the global cancer biologics industry growth is the rising global incidence of cancer.

The ortho-biologics market size is estimated to grow by USD 2,638.44 million between 2022 and 2027 accelerating at a CAGR of 7.88% during the forecast period. This ortho biologics market report extensively covers market segmentation by application (spinal fusion, reconstructive surgery, trauma repair, and others), product (bone graft substitutes, viscosupplementation, and stem cells), and geography (North America, Europe, Asia, and the Rest of World (ROW)). The increasing prevalence of orthopedic disorders coupled with an aging population is a key factor in the growth of the market.

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Product Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022 

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global biologics CDMO market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global biologics CDMO market 2017 - 2021 ($ billion)

• 4.2 Type Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ billion)

• 4.3 Product type Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Product type Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

• 6.1 Market segments 
• Exhibit 30: Chart on Type - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

• 6.2 Comparison by Type 
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type

• 6.3 Mammalian - Market size and forecast 2022-2027
• Exhibit 34: Chart on Mammalian - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on Mammalian - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on Mammalian - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Mammalian - Year-over-year growth 2022-2027 (%)

• 6.4 Microbial - Market size and forecast 2022-2027
• Exhibit 38: Chart on Microbial - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Microbial - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Microbial - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Microbial - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Type 
• Exhibit 42: Market opportunity by Type ($ billion)

7 Market Segmentation by Product Type

• 7.1 Market segments 
• Exhibit 43: Chart on Product Type - Market share 2022-2027 (%)
• Exhibit 44: Data Table on Product Type - Market share 2022-2027 (%)

• 7.2 Comparison by Product Type 
• Exhibit 45: Chart on Comparison by Product Type
• Exhibit 46: Data Table on Comparison by Product Type

• 7.3 Biologics - Market size and forecast 2022-2027
• Exhibit 47: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 48: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 49: Chart on Biologics - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Biologics - Year-over-year growth 2022-2027 (%)

• 7.4 Biosimilars - Market size and forecast 2022-2027
• Exhibit 51: Chart on Biosimilars - Market size and forecast 2022-2027 ($ billion)
• Exhibit 52: Data Table on Biosimilars - Market size and forecast 2022-2027 ($ billion)
• Exhibit 53: Chart on Biosimilars - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Biosimilars - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Product Type 
• Exhibit 55: Market opportunity by Product Type ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 57: Chart on Market share by geography 2022-2027 (%)
• Exhibit 58: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 59: Chart on Geographic comparison
• Exhibit 60: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 China - Market size and forecast 2022-2027
• Exhibit 81: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 82: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 83: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 France - Market size and forecast 2022-2027
• Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ billion)
• Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ billion)
• Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%)

• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 93: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 94: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 95: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 97: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers 

• 10.2 Market challenges 

• 10.3 Impact of drivers and challenges 
• Exhibit 98: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends 

11 Vendor Landscape

• 11.1 Overview 

• 11.2 Vendor landscape 
• Exhibit 99: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 100: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 101: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 102: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 103: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 104: AbbVie Inc. - Overview
• Exhibit 105: AbbVie Inc. - Product / Service
• Exhibit 106: AbbVie Inc. - Key news
• Exhibit 107: AbbVie Inc. - Key offerings

• 12.4 Binex Co. Ltd. 
• Exhibit 108: Binex Co. Ltd. - Overview
• Exhibit 109: Binex Co. Ltd. - Product / Service
• Exhibit 110: Binex Co. Ltd. - Key offerings

• 12.5 Boehringer Ingelheim International GmbH
• Exhibit 111: Boehringer Ingelheim International GmbH - Overview
• Exhibit 112: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 113: Boehringer Ingelheim International GmbH - Key news
• Exhibit 114: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 115: Boehringer Ingelheim International GmbH - Segment focus

• 12.6 Bora Pharmaceuticals Co. Ltd. 
• Exhibit 116: Bora Pharmaceuticals Co. Ltd. - Overview
• Exhibit 117: Bora Pharmaceuticals Co. Ltd. - Product / Service
• Exhibit 118: Bora Pharmaceuticals Co. Ltd. - Key offerings

• 12.7 Catalent Inc. 
• Exhibit 119: Catalent Inc. - Overview
• Exhibit 120: Catalent Inc. - Business segments
• Exhibit 121: Catalent Inc. - Key news
• Exhibit 122: Catalent Inc. - Key offerings
• Exhibit 123: Catalent Inc. - Segment focus

• 12.8 Evonik Industries AG 
• Exhibit 124: Evonik Industries AG - Overview
• Exhibit 125: Evonik Industries AG - Business segments
• Exhibit 126: Evonik Industries AG - Key news
• Exhibit 127: Evonik Industries AG - Key offerings
• Exhibit 128: Evonik Industries AG - Segment focus

• 12.9 FUJIFILM Holdings Corp 
• Exhibit 129: FUJIFILM Holdings Corp - Overview
• Exhibit 130: FUJIFILM Holdings Corp - Business segments
• Exhibit 131: FUJIFILM Holdings Corp - Key offerings
• Exhibit 132: FUJIFILM Holdings Corp - Segment focus

• 12.10 Grifols SA 
• Exhibit 133: Grifols SA - Overview
• Exhibit 134: Grifols SA - Business segments
• Exhibit 135: Grifols SA - Key offerings
• Exhibit 136: Grifols SA - Segment focus

• 12.11 JRS PHARMA GmbH and Co. KG 
• Exhibit 137: JRS PHARMA GmbH and Co. KG - Overview
• Exhibit 138: JRS PHARMA GmbH and Co. KG - Product / Service
• Exhibit 139: JRS PHARMA GmbH and Co. KG - Key offerings

• 12.12 Lonza Group Ltd. 
• Exhibit 140: Lonza Group Ltd. - Overview
• Exhibit 141: Lonza Group Ltd. - Business segments
• Exhibit 142: Lonza Group Ltd. - Key news
• Exhibit 143: Lonza Group Ltd. - Key offerings
• Exhibit 144: Lonza Group Ltd. - Segment focus

• 12.13 Novartis AG 
• Exhibit 145: Novartis AG - Overview
• Exhibit 146: Novartis AG - Business segments
• Exhibit 147: Novartis AG - Key offerings
• Exhibit 148: Novartis AG - Segment focus

• 12.14 Rentschler Biopharma SE 
• Exhibit 149: Rentschler Biopharma SE - Overview
• Exhibit 150: Rentschler Biopharma SE - Product / Service
• Exhibit 151: Rentschler Biopharma SE - Key offerings

• 12.15 Samsung Biologics Co. Ltd. 
• Exhibit 152: Samsung Biologics Co. Ltd. - Overview
• Exhibit 153: Samsung Biologics Co. Ltd. - Product / Service
• Exhibit 154: Samsung Biologics Co. Ltd. - Key offerings

• 12.16 Toyobo Co. Ltd. 
• Exhibit 155: Toyobo Co. Ltd. - Overview
• Exhibit 156: Toyobo Co. Ltd. - Business segments
• Exhibit 157: Toyobo Co. Ltd. - Key offerings
• Exhibit 158: Toyobo Co. Ltd. - Segment focus

• 12.17 WuXi Biologics Cayman Inc. 
• Exhibit 159: WuXi Biologics Cayman Inc. - Overview
• Exhibit 160: WuXi Biologics Cayman Inc. - Product / Service
• Exhibit 161: WuXi Biologics Cayman Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 162: Inclusions checklist
• Exhibit 163: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 164: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 165: Research methodology
• Exhibit 166: Validation techniques employed for market sizing
• Exhibit 167: Information sources

• 13.5 List of abbreviations 
• Exhibit 168: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED